Bradley JS, Antadze T, Ninov B, et al. - Researchers aimed at evaluating the safety and efficacy of tedizolid (administered as tedizolid phosphate) vs active antibacterial comparators for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adolescents via performing randomized, assessor-blind, global phase 3 study. Among 121 enrolled participants, 120 received treatment (tedizolid, n = 91; comparator, n = 29). Both treatment groups exhibited high clinical success rates: 96.7% and 93.1% at the test-of-cure visit for the tedizolid and comparator groups, respectively. Overall outcomes suggest that safety and efficacy demonstrated by tedizolid are similar to that of comparators for the treatment of ABSSSIs in adolescents.